Medicus Pharma Gains FDA 'Study May Proceed' Authorization for SkinJect Registrational Trial in Gorlin Syndrome

Medicus Pharma's receipt of FDA 'Study May Proceed' authorization for its registrational SkinJect® trial in Gorlin Syndrome signals how the agency is engaging with novel topical delivery platforms at the IND stage, a procedural checkpoint that clinical operations and regulatory affairs teams at similar-stage biotechs will recognize as a meaningful green light for full trial activation.

The Philadelphia-based company also secured IRB authorization and positive FDA feedback for an optimized Teverelix® Phase 2 study in acute urinary retention, and received clearance from the UAE Department of Health to initiate the genomics-enabled PRECISION-E2 study evaluating Teverelix® in women with symptomatic endometriosis. The dual-platform progression across distinct regulatory jurisdictions reflects a broadening clinical footprint, though each program carries its own timeline and execution risk.

On the financial side, Medicus raised approximately $40 million year-to-date through a combination of equity issuances under an expanded at-the-market program and a new secured financing facility. Cash and cash equivalents stood at $15.2 million as of June 30, 2026, up from $9.7 million at the same point in 2025. However, the company's Form 10-Q filed for the quarter discloses substantial doubt about its ability to continue as a going concern without additional financing, a material qualifier that supply-chain and procurement counterparts engaged with Medicus should factor into continuity planning.

Operating expenses reached $11.5 million in Q2 2026, nearly double the $6.0 million recorded in Q2 2025, driven primarily by R&D spend climbing from $1.4 million to $4.9 million as clinical programs scaled. Net loss for the quarter was $11.7 million, versus $6.2 million in the prior-year period. General and administrative expenses also rose, from $4.6 million to $6.6 million, reflecting the infrastructure costs of managing a multi-program, multi-jurisdiction development portfolio.

For regulatory affairs leads tracking FDA's feedback mechanisms on novel delivery platforms, the SkinJect authorization offers a data point on agency posture toward non-traditional dermatological modalities ahead of what would be a registrational-stage interaction, the kind of early-signal read that informs protocol design decisions well before a pre-NDA meeting is warranted.

The next measurable outcome will be enrollment progress in the SkinJect registrational study and interim data readouts from the Teverelix® acute urinary retention trial, both of which the company has flagged as anticipated near-term catalysts.

Source: Medicus Pharma Ltd. via ACCESS Newswire, August 12, 2026.